cancer to salvage be a simpler and more convenient practice. intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review7 Cerebrospinal fluid Unknown Unknown Intraventricular This study investigated pharmacokinetic parameters of pharmacokinetics after administration via Ommaya etoposide in CSF following intraventricular administration different dosage reservoir. utilising different dosage schedules in 9 patients aged 3-32 regimens of years. Pharmacokinetics of etoposide following intraventricular intraventricular administration exhibited a linear two-compartment model. etoposide3 Intrathecal Unknown - Unknown 1st patient: 0.5mg diluted This reference describes two case reports of treated “i.v. patients’ administration of etoposide in 2mL of saline with 0.5mg etoposide on five consecutive days, followed by a etoposide in the administered second course of 0.5mg etoposide twice daily (2 hours apart for formulation” treatment of malignant intraventricularly via the first patient, 12 hours apart for the second) for 5 days, 21 meningitis: feasibility subcutaneous reservoir. days after the first course. No systemic toxicities were and pharmacokinetic 2nd patient: 0.5mg diluted demonstrated in either patient. data6 in 2mL of saline administered intrathecally (unclear where this administration took place). Comparison of UK Marketed Products with Products Used in References Note: Products with the same, or similar excipients, may utilise different concentrations. Vepesid, Bristol-Myers Squibb, Etoposid Ebewe, BASF Pharma, Austria5 ETO-GRY, Teva, Germany4 Germany1,4 Absolute ethyl alcohol, Benzyl alcohol, Benzyl alcohol, Citric acid, Ethanol, Macrogol Citric acid, Ethanol, Macrogol 300, Polysorbate Citric acid, Macrogol 300, Polysorbate 80 300, Nitrogen, Polysorbate 80 80 Teva UK Limited Citric acid, Ethanol, Macrogol Similar content except: Similar content except: 300, Polysorbate 80 UK product does not contain UK product does not contain Same content Most similar to the benzyl alcohol potentially benzyl alcohol potentially – – ETO-GRY product beneficial beneficial
cancer to salvage intrathecal etoposide subsequent to failure of first-line methotrexate: a case report and literature review7 be a simpler and more convenient practice. Cerebrospinal fluid pharmacokinetics after different dosage regimens of intraventricular etoposide3 Unknown Unknown Intraventricular administration via Ommaya reservoir. This study investigated pharmacokinetic parameters of etoposide in CSF following intraventricular administration utilising different dosage schedules in 9 patients aged 3-32 years. Pharmacokinetics of etoposide following intraventricular administration exhibited a linear two-compartment model. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data6 Unknown - “i.v. etoposide formulation” Unknown 1st patient: 0.5mg diluted in 2mL of saline administered intraventricularly via subcutaneous reservoir. 2nd patient: 0.5mg diluted in 2mL of saline administered intrathecally (unclear where this administration took place). This reference describes two case reports of patients’ treated with 0.5mg etoposide on five consecutive days, followed by a second course of 0.5mg etoposide twice daily (2 hours apart for the first patient, 12 hours apart for the second) for 5 days, 21 days after the first course. No systemic toxicities were demonstrated in either patient. Comparison of UK Marketed Products with Products Used in References Note: Products with the same, or similar excipients, may utilise different concentrations. Vepesid, Bristol-Myers Squibb, Germany1,4 Etoposid Ebewe, BASF Pharma, Austria5 ETO-GRY, Teva, Germany4 Absolute ethyl alcohol, Benzyl alcohol, Citric acid, Macrogol 300, Polysorbate 80 Benzyl alcohol, Citric acid, Ethanol, Macrogol 300, Nitrogen, Polysorbate 80 Citric acid, Ethanol, Macrogol 300, Polysorbate 80 Teva UK Limited Most similar to the ETO-GRY product Citric acid, Ethanol, Macrogol 300, Polysorbate 80 Similar content except: UK product does not contain benzyl alcohol – potentially beneficial Similar content except: UK product does not contain benzyl alcohol – potentially beneficial Same content
Etoposide-Intrathecal-Use-final.docx